DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Piccart M, Procter M, Fumagalli D. et al.
Interim overall survival analysis of APHINITY (BIG 4–11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer.
San Antonio Breast Cancer Symposium 2019;
2019: GS1-04
We do not assume any responsibility for the contents of the web pages of other providers.